Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 12/20 | 0.74 |
| ▸ | HTR2B | P41595 | 2/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYBB | P04839 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.55 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.55 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30812968 | 0.85 | ALOX5 (1.00) | ALOX5HTR2BHTR7MEN1GAA | |
| SCHEMBL2483714 | 0.85 | ALOX5 (1.00) | ALOX5HTR2BHTR7MEN1GAA | |
| SCHEMBL27344785 | 0.83 | ALOX5 (0.51) | ALOX5HTR2BHTR7MEN1CYBB | |
| SCHEMBL27344712 | 0.83 | ALOX5 (0.51) | ALOX5HTR2BHTR7MEN1CYBB | |
| SCHEMBL27344709 | 0.82 | ALOX5 (0.51) | ALOX5HTR2BHTR7MEN1CYBB | |
| SCHEMBL1928583 | 0.80 | ALOX5 (0.68) | ALOX5HTR2BHTR7MAPTKDM4E | |
| SCHEMBL27345997 | 0.79 | ACE2 (0.50) | ALOX5HTR2BHTR7MEN1CYBB | |
| SCHEMBL27344516 | 0.79 | ALOX5 (0.48) | ALOX5HTR2BHTR7MEN1CYBB | |
| Phenoxazine SCHEMBL6270610 | 0.77 | ALOX5 (0.77) | ALOX5HTR2BHTR7MEN1GAA | |
| SCHEMBL28400911 | 0.75 | ALOX5 (0.83) | ALOX5HTR2BHTR7GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245297-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2023-12-28 | — | — | WO | disclosed |
| US-7384933-B2 | Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | CAPN1, MYH10, CAPN9 | ALOX5 492/4885HTR2B 2413/4885HTR7 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.